Compare CENN & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENN | NCEL |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | 11 |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 10.3M |
| IPO Year | 2017 | N/A |
| Metric | CENN | NCEL |
|---|---|---|
| Price | $3.88 | $2.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 17.1K |
| Earning Date | 05-15-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,080,161.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.07 | $1.83 |
| 52 Week High | $4.42 | $4.70 |
| Indicator | CENN | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 89.74 | 53.76 |
| Support Level | $0.26 | $2.50 |
| Resistance Level | N/A | $3.16 |
| Average True Range (ATR) | 0.16 | 0.19 |
| MACD | 0.46 | 0.05 |
| Stochastic Oscillator | 85.43 | 84.15 |
Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles powered by either electricity or hydrogen energy sources. The company's commercial vehicles are designed to serve a variety of fleet and municipal organizations in support of city services, last-mile delivery, and other commercial applications. It has developed a series of commercial vehicle models, including Metro, Logistar, Logimax, Avantier, Teemak, and Antric One. In addition, the company has introduced an open-platform, programmable all-electric iChassis platform, designed for automated and autonomous driving. Geographically, the company generates maximum revenue from vehicle sales in the United States, and also has a presence in Europe, Asia, and other regions.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.